抗小鼠TIGIT单克隆抗体(克隆号1F4) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007280.m2a
体内实验级重组抗小鼠TIGIT单克隆抗体，小鼠IgG2a Kappa（克隆号1F4，货号：PA007280.m2a）是用哺乳动物细胞生产的重组抗体，可用于ELISA，流式细胞术，中和，功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠TIGIT蛋白影响的生物学途径的测定等研究，纯度: >95%。其不变区为小鼠IgG2a kappa (mIgG2a或m2a)，可与重组小鼠IgG2a同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
- 产品参数
- 文献
- More Offers
| 货号 | PA007280.m2a |
|---|---|
| 产品名称 | 抗小鼠TIGIT单克隆抗体(克隆号1F4) ，体内实验级重组，小鼠IgG2a Kappa | Syd Labs PA007280.m2a |
| 英文名 | In Vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody（Clone 1F4）,Mouse IgG2a Kappa |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | 悉得（Syd Labs） |
| 别称 | VSIG9, VSTM3, WUCAM, T-cell immunoreceptor with Ig and ITIM domains, T cell immunoreceptor with Ig and ITIM domains |
| 概述 | 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | 1F4 |
| 同种型 | 小鼠 IgG2a Kappa |
| 应用 | ELISA，流式细胞术（FC），中和（neutralization），功能测定如生物分析 PK 和 ADA 测定，以及那些用于研究受小鼠TIGIT蛋白影响的生物学途径的测定。 |
| 免疫源 | 抗小鼠TIGIT单克隆抗体(克隆号: 1F4)是用哺乳动物细胞生产的 |
| 抗体形式 | 0.2微米过滤溶液，pH 7.4，无稳定剂或防腐剂 |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗小鼠TIGIT单克隆抗体(克隆号1F4)，小鼠IgG2a Kappa用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 如果保存在2 至 8°C，自收到之日起可保存1个月。如果保存在-20 至 -70°C，自收到之日起可保存 12个月。 |
| 注意事项 | PA007280.m2a 悉得（Syd Labs）提供重组小鼠 IgG2a同型对照抗体和重组人 IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | 悉得（Syd Labs）在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系悉得（Syd Labs）中国代理商。 关于悉得（Syd Labs）产品如果有任何技术或其它问题，欢迎随时联系悉得（Syd Labs）国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
描述
了解更多抗小鼠TIGIT单克隆抗体引用文献，请查看：抗小鼠TIGIT单抗引用文献
抗小鼠TIGIT抗体参考文献:
1. Targeting TIGIT for cancer immunotherapy: recent advances and future directions
Peng Zhang,et al.Biomark Res. 2024.PMCID: PMC10790541
“As a newly identified checkpoint, T cell immunoreceptor with immunoglobulin and tyrosine-based inhibitory motif (ITIM) domain (TIGIT) is highly expressed on CD4+ T cells, CD8+ T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). TIGIT has been associated with NK cell exhaustion in vivo and in individuals with various cancers. It not only modulates NK cell survival but also mediates T cell exhaustion. As the primary ligand of TIGIT in humans, CD155 may be the main target for immunotherapy due to its interaction with TIGIT. It has been found that the anti-programmed cell death protein 1 (PD-1) treatment response in cancer immunotherapy is correlated with CD155 but not TIGIT. Anti-TIGIT alone and in combination with anti-PD-1 agents have been tested for cancer immunotherapy. Although two clinical studies on advanced lung cancer had positive results, the TIGIT-targeted antibody, tiragolumab, recently failed in two new trials. In this review, we highlight the current developments on TIGIT for cancer immunotherapy and discuss the characteristics and functions of TIGIT.”
2. Studying TIGIT activity against tumors through the generation of knockout mice
Ahmed Rishiq,et al.Oncoimmunology. 2023.PMCID:PMC10228407
“The use of antibodies to block inhibitory receptors, primarily anti-PD1 and CTLA4 (known as checkpoint therapy) revolutionized cancer treatment. However, despite these successes, the majority of cancer patients do not respond to the checkpoint treatment, emphasizing the need for development of additional therapies, which are based on other inhibitory receptors. Human TIGIT is an inhibitory receptor expressed by Natural Killer (NK) and T cells and is mainly known to interact with PVR, Nectin-2, Nectin-3, and Nectin-4. Whether mouse TIGIT interacts with all of these ligands is still unclear. Additionally, the in vivo function of TIGIT against tumors is not completely understood. Here, we demonstrate that mouse TIGIT interacts with and is inhibited by mPVR only. Using CRISPR-Cas9 technology, we generated TIGIT-deficient mice and demonstrated that NK cell cytotoxicity and degranulation against two tumor types were lower in WT mice when compared to the TIGIT KO mice. Moreover, in vivo tumor progression was slower in TIGIT KO than in WT mice. Taken together, our data established that mTIGIT has only one ligand, PVR, and that in the absence of TIGIT tumors are killed better both in vitro and in vivo.”
3. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT)
Shuguang Zuo,et al.EBioMedicine. 2021.PMCID:PMC7878184
“Background:Oncolytic virotherapy with vaccinia virus (VV) can lead to effective anti-tumor immunity by turning “cold” tumors into “hot” tumors. However, its therapeutic potential is affected by the tumor’s local immunosuppressive tumor microenvironment (TME). Therefore, it is necessary to explore the use of immune checkpoint inhibitors to arm oncolytic VVs to enhance their anti-tumor efficacy.Methods:A novel recombinant oncolytic VV, VV-α-TIGIT, which encoded a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT) was generated by homologous recombination with a shuttle plasmid. The anti-tumor efficacy of the VV-α-TIGIT was investigated in several subcutaneous and ascites tumor models.Findings:The functional α-TIGIT was sufficiently produced and secreted by tumor cells infected with VV-α-TIGIT, which effectively replicated in tumor cells leading to significant oncolysis. Intratumoral injection of VV-α-TIGIT improved anti-tumor efficacy in several murine subcutaneous tumor models compared to VV-Control (without α-TIGIT insertion). Intraperitoneal injection of VV-α-TIGIT achieved approximately 70% of complete tumor regression in an ascites tumor model. At the same time, treatment with VV-α-TIGIT significantly increased the recruitment and activation of T cells in TME. Moreover, the in vivo anti-tumor activity of VV-α-TIGIT was largely dependent on CD8+ T cell-mediated immunity. Finally, the tumor-bearing mice cured of VV-α-TIGIT treatment resisted rechallenge with the same tumor cells, suggesting a long-term persistence of tumor-specific immunological memory.Interpretation:The recombinant oncolytic virus VV-α-TIGIT successfully combines the advantages of oncolytic virotherapy and intratumorally expression of immune checkpoint inhibitor against TIGIT. This novel strategy can provide information on the optimal design of novel antibody-armed oncolytic viruses for cancer immunotherapy.Funding:This work was supported by the National Natural Science Foundation of China (81773255, 81472820, and 81700037), the Science and Technology Innovation Foundation of Nanjing University (14913414), and the Natural Science Foundation of Jiangsu Province of China (BK20171098).”
悉得（Syd Labs）抗小鼠TIGIT单克隆抗体，小鼠IgG2a Kappa（货号：PA007280.m2a）推荐同型对照抗体:
重组小鼠IgG2a同型对照抗体，体内实验级（In Vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody）
悉得（Syd Labs）相关重组IgG同型对照抗体（Recombinant IgG Reference Antibodies）:
重组小鼠IgG2a同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants）
重组人IgG1同型对照抗体和突变体，体内实验级（In Vivo Grade Recombinant Human IgG1 Isotype Control Antibody and Mutants）
悉得（Syd Labs）提供以下抗人 CD3抗体（anti-human CD3 antibodies）:
Muromonab生物类似药，科研级，抗人CD3单克隆抗体(克隆号: OKT3)（Muromonab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)）
Teplizumab 生物类似药，科研级，抗人CD3单克隆抗体(克隆号: OKT3)（Teplizumab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)）
Foralumab 生物类似药，科研级，抗人CD3单克隆抗体(克隆号: OKT3)（Foralumab biosimilar, research grade, anti-human CD3 monoclonal antibody (Clone: OKT3)）
抗人 CD3单克隆抗体(克隆号: OKT3)（Anti-human CD3 monoclonal antibody (Clone: OKT3)）
抗人 CD3单克隆抗体(克隆号: SP34-2)（Anti-human CD3 monoclonal antibody (Clone: SP34-2)）
抗人 CD3单克隆抗体(克隆号:UCHT1)（Anti-human CD3 monoclonal antibody (Clone:UCHT1)）
悉得（Syd Labs）提供以下抗小鼠 CD3抗体（ anti-mouse CD3 antibodies）:
抗小鼠 CD3e 单克隆抗体(克隆号: 145-2C11)（Anti-mouse CD3e monoclonal antibody (Clone: 145-2C11)）
抗小鼠 CD3e 单克隆抗体(克隆号: 500A2)（Anti-mouse CD3e monoclonal antibody (Clone: 500A2)）
抗小鼠 CD3单克隆抗体(克隆号: 17A2)（Anti-mouse CD3 monoclonal antibody (Clone: 17A2)）
请记住我们的产品信息: 体内实验级重组抗小鼠TIGIT单克隆抗体(克隆号1F4)，小鼠IgG2a Kappa: PA007280.m2a Syd Labs In vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody (Clone: 1F4), Mouse IgG2a Kappa 。